Global Blood Therapeutics, Inc.
GBT · NASDAQ
6/30/2022 | 3/31/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Market Cap | $2,095,754 | $2,246,130 | $1,887,590 | $1,603,331 |
| - Cash | $261,152 | $391,803 | $684,717 | $382,869 |
| + Debt | $658,386 | $659,051 | $659,617 | $229,952 |
| Enterprise Value | $2,492,988 | $2,513,378 | $1,862,490 | $1,450,414 |
| Revenue | $71,550 | $55,160 | $56,099 | $52,052 |
| % Growth | 29.7% | -1.7% | 7.8% | – |
| Gross Profit | $70,137 | $54,105 | $54,945 | $51,222 |
| % Margin | 98% | 98.1% | 97.9% | 98.4% |
| EBITDA | -$71,571 | -$70,782 | -$80,494 | -$65,090 |
| % Margin | -100% | -128.3% | -143.5% | -125% |
| Net Income | -$82,470 | -$81,423 | -$91,496 | -$70,988 |
| % Margin | -115.3% | -147.6% | -163.1% | -136.4% |
| EPS Diluted | -1.26 | -1.26 | -1.42 | -1.13 |
| % Growth | 0% | 11.3% | -25.7% | – |
| Operating Cash Flow | -$44,308 | -$71,853 | -$67,926 | -$65,310 |
| Capital Expenditures | -$384 | -$252 | -$1,053 | -$260 |
| Free Cash Flow | -$44,692 | -$72,105 | -$68,979 | -$65,570 |